Marino Garcia, CEO and President of Dianthus Therapeutics (NASDAQ: DNTH), sold 122,918 shares of common stock on March 12, 2026, at prices ranging from $80.69 to $85.53, receipts totaling approximately $10 million, according to a Form 4 filed with the Securities and Exchange Commission. The stock has been trading near its 52-week high of $88.02 after a 265% gain over the past year.
The transactions were carried out under a pre-arranged 10b5-1 trading arrangement that Garcia adopted on November 17, 2025, the filing shows. On the same day as the disposition, Garcia exercised options to acquire 122,918 shares of Dianthus common stock at an exercise price of $6.70 per share, for an aggregate exercise cost of $823,550.
Following the option exercise and the share sale, Garcia is reported to directly own 0 shares of Dianthus Therapeutics common stock.
Company financial posture and third-party valuation note
External analysis from InvestingPro, cited in the filings and company communications, indicates that Dianthus shares currently appear overvalued relative to InvestingPro’s Fair Value estimate. The company is identified as unprofitable, reporting negative earnings per share of $4.20. The market capitalization referenced in the materials is $4.03 billion. The InvestingPro coverage also notes the availability of 16 additional InvestingPro Tips for investors seeking deeper analysis of DNTH’s outlook.
Recent capital raises
Dianthus has completed major equity raises in recent transactions. The company closed a public offering that generated approximately $719 million in gross proceeds by selling 8,470,989 shares of common stock at $81.00 per share, along with pre-funded warrants that cover an additional 402,468 shares. These financing activities follow an earlier announcement of a $625 million stock offering at the same $81.00 per-share price.
In addition to those closings, Dianthus commenced a $400 million stock offering intended to support its clinical and preclinical development initiatives. Together, these offerings reflect a concentrated effort to secure financing for the company’s pipeline and operations.
Clinical progress and analyst reactions
Analysts have adjusted their views in light of recent trial data. Raymond James upgraded Dianthus to a Strong Buy rating and raised its price target to $123, citing encouraging interim results from the Phase 3 CAPTIVATE trial in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Clear Street likewise increased its price target to $130 and retained a Buy rating after noting positive trial data. Both firms pointed to the decision to advance the CAPTIVATE program to Part B as a driver of their revised outlooks.
These developments - an insider share sale executed under a pre-established plan, simultaneous option exercises, sizeable equity financings, and positive Phase 3 interim data prompting analyst upgrades - together mark a busy period for Dianthus. The company continues to balance funding needs with clinical execution while external analysis flags valuation and profitability as considerations for investors.